Oxford University has a special responsibility to ensure jabs reach the Global South

Oxford University stands to make many millions from its vaccine spin-out. Yet the deals it has done, and the lack of a patent waiver, limit the ability of the Global South to manufacture AstraZeneca jabs. Luke McDonagh (LSE) argues that the university, as a wealthy and publicly funded institution, has a special responsibility to ensure the vaccine reaches countries where thousands of people are dying from COVID every day.